OPEN LABEL INTERVENTIONAL MULTICENTER PHASE 3B STUDY TO EVALUATE SKELETAL RESPONSE TO ELIGLUSTAT IN ADULT PATIENTS WHO SUCCESSFULLY COMPLETED THE PHASE 2 OR PHASE 3 STUDIES.

Registry ID

EFC13781

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

GENZYME, A SANOFI COMPANY

Start date

2016-03-16

Completion date

2021-12-16

Last update

2015-06-09

Conditions

• GAUCHER DISEASE TYPE 1

Related clinical trials

• A PHASE 3 SAFETY AND EFFICACY TRIAL OF FLT201 GENE THERAPY IN PATIENTS WITH GAUCHER DISEASE TYPE 1
• AN ADAPTIVE, OPEN-LABEL, MULTINATIONAL PHASE 1/2 STUDY OF THE SAFETY AND EFFICACY OF EX VIVO, LENTIVIRAL VECTOR-MEDIATED GENE THERAPY AVR-RD-02 FOR SUBJECTS WITH TYPE 1 GAUCHER DISEASE

View on source registry